0000903423-18-000373.txt : 20180703 0000903423-18-000373.hdr.sgml : 20180703 20180703175939 ACCESSION NUMBER: 0000903423-18-000373 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180702 FILED AS OF DATE: 20180703 DATE AS OF CHANGE: 20180703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GLAXOSMITHKLINE PLC CENTRAL INDEX KEY: 0001131399 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] STATE OF INCORPORATION: X0 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38550 FILM NUMBER: 18938776 BUSINESS ADDRESS: STREET 1: 980 GREAT WEST ROAD CITY: BRENTFORD MIDDLESEX STATE: X0 ZIP: TW8 9GS BUSINESS PHONE: 011442080475000 MAIL ADDRESS: STREET 1: 980 GREAT WEST ROAD CITY: BRENTFORD MIDDLESEX STATE: X0 ZIP: TW8 9GS ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Translate Bio, Inc. CENTRAL INDEX KEY: 0001693415 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 611807780 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 29 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 617-945-7361 MAIL ADDRESS: STREET 1: 29 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: RaNA Therapeutics, Inc. DATE OF NAME CHANGE: 20161228 4 1 translate.xml OWNERSHIP DOCUMENT X0306 4 2018-07-02 1 0001693415 Translate Bio, Inc. TBIO 0001131399 GLAXOSMITHKLINE PLC 980 GREAT WEST ROAD BRENTFORD MIDDLESEX X0 TW8 9GS UNITED KINGDOM 0 0 1 0 Common Stock 2018-07-02 4 C 0 1674016 A 1674016 I See Footnote Common Stock 2018-07-02 4 C 0 1300116 A 2974132 I See Footnote Common Stock 2018-07-02 4 C 0 454550 A 3428682 I See Footnote Common Stock 2018-07-02 4 P 0 269230 13.00 A 3697912 I See Footnote Series A Preferred Stock 2018-07-02 4 C 0 9300000 0 D Common Stock 1674016 0 I See Footnote Series B Preferred Stock 2018-07-02 4 C 0 7222797 0 D Common Stock 1300116 0 I See Footnote Series C Preferred Stock 2018-07-02 4 C 0 2525253 0 D Common Stock 454550 0 I See Footnote S.R. One, Limited acquired 269,230 Common Stock of the Issuer in connection with the Issuer's initial public offering. The Series A, Series B and Series C Preferred Stock were converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B, and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person"). /s/ Victoria Whyte, Company Secretary, GlaxoSmithKline Plc 2018-07-02